ArticleJournal of cardiovascular development and disease2022
A Novel Patent Ductus Arteriosus Severity Score to Predict Clinical Outcomes in Premature Neonates.
Article in Journal of cardiovascular development and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Making sense of the evidence: designing randomised controlled trials for preterm infants with high-shunt volume patent ductus arteriosus.Archives of disease in childhood. Fetal and neonatal edition · 2026Review
- Beyond diameter: redefining echocardiography criteria in trials of early PDA therapy.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Artificial intelligence for patent ductus arteriosus-a systematic review.Frontiers in pediatrics · 2026Review
- Adding Early Postnatal Parameters of Ventilation to Prognostic Models for Pulmonary Outcome in Very Preterm Infants.Pediatric pulmonology · 2025Article
- Perinatal Factors Associated with Successful Pharmacologic Closure of the Patent Ductus Arteriosus in Premature Infants.Pediatric cardiology · 2025Article
- Machine learning-based prediction of hemodynamically significant patent ductus arteriosus in preterm neonates: a pioneering insight.Frontiers in pediatrics · 2025Article
- Device Closure of Hemodynamically Significant Patent Ductus Arteriosus in Premature Infants.JACC. Advances · 2024Review
- Patent Ductus Arteriosus and Lung Magnetic Resonance Imaging Phenotype in Moderate and Severe Bronchopulmonary Dysplasia-Pulmonary Hypertension.American journal of respiratory and critical care medicine · 2024Article
- Predictive analytics in bronchopulmonary dysplasia: past, present, and future.Frontiers in pediatrics · 2024Review
- Personalized Evidence-Based Management of Patent Ductus Arteriosus in Preterm Infants.Journal of cardiovascular development and disease · 2023Review
- PD(AI): the role of artificial intelligence in the management of patent ductus arteriosus.Journal of perinatology : official journal of the California Perinatal Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patent Ductus Arteriosus (PDA) in premature neonates has been associated with comorbidities including chronic lung disease (CLD), and death. However, the treatment of PDA remains controversial. There have been several echocardiographic variables previously used to determine the hemodynamic significance of PDA but their utility in early prediction of clinical outcomes is not well studied. Objective: The objective of our study was to evaluate the use of a severity scoring system incorporating markers of systemic under perfusion, pulmonary over perfusion and left ventricular (LV) function in predicting clinical outcomes in premature neonates. Methods: It is a single center prospective observational study involving newborns < 32 weeks’ gestation. An echocardiogram was done within seven days of life to measure variables previously known to predict severity of shunting in PDA including pulmonary perfusion index (PPI). Predictors of CLD/death were identified using multivariate logistic regression. A severity score was derived and its ability to predict clinical outcomes was tested using a receiver operating characteristic curve. Results: We studied 98 infants with a mean (SD) gestation of 28.9 ± 1.91 weeks and birth weight of 1228.06 ± 318.94 g, respectively. We identified five echocardiographic variables along with gestational age that was independently associated with the outcome variable (PPI, LV output, Superior Mesenteric Artery [SMA] Velocity Time Integral [VTI], Peak diastolic flow velocity in Pulmonary Vein [PV Vd], and reversal of flow in diastole in descending aorta [DFR]). The range of severity score was 0 (low risk) to 12 (high risk). A higher score was associated with the primary outcome variable of CLD/death (7.5 [1.2] vs. 3.6 [1.5], p < 0.001). Our severity score had an area under the curve of 0.97 (95% CI 0.93−0.99, p < 0.001) for predicting CLD/death. Conclusion: Our new PDA severity score of 5.5 has a sensitivity and specificity of 94% and 93%, and positive and negative predictive values of 94% and 93%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.